A RANDOMIZED PHASE III STUDY OF TAS-118 VERSUS S-1 IN PATIENTS WITH GEMCITABINE-REFRACTORY ADVANCED PANCREATIC CANCER
Latest Information Update: 28 Jan 2022
At a glance
- Drugs Gimeracil/oteracil/tegafur/folinic acid (Primary) ; Gimeracil/oteracil/tegafur
- Indications Ductal carcinoma; Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Acronyms GRAPE
- Sponsors Taiho Pharmaceutical
- 12 Nov 2018 Results published in the European Journal of Cancer
- 03 Aug 2017 Status changed from active, no longer recruiting to completed.
- 06 Jun 2017 Primary endpoint (Overall survival) has not been met as per the results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology